[go: up one dir, main page]

DK1267925T3 - Behandling af svampeinfektion mod antifungale polyener eller beta-glucansyntesehæmmere kombineret med anti-hsp90-antistoffer - Google Patents

Behandling af svampeinfektion mod antifungale polyener eller beta-glucansyntesehæmmere kombineret med anti-hsp90-antistoffer

Info

Publication number
DK1267925T3
DK1267925T3 DK01911971T DK01911971T DK1267925T3 DK 1267925 T3 DK1267925 T3 DK 1267925T3 DK 01911971 T DK01911971 T DK 01911971T DK 01911971 T DK01911971 T DK 01911971T DK 1267925 T3 DK1267925 T3 DK 1267925T3
Authority
DK
Denmark
Prior art keywords
treatment
beta
fungal infection
synthesis inhibitors
glucan synthesis
Prior art date
Application number
DK01911971T
Other languages
Danish (da)
English (en)
Inventor
James Peter Burnie
Original Assignee
Neutec Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Ltd filed Critical Neutec Pharma Ltd
Application granted granted Critical
Publication of DK1267925T3 publication Critical patent/DK1267925T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK01911971T 2000-04-06 2001-03-20 Behandling af svampeinfektion mod antifungale polyener eller beta-glucansyntesehæmmere kombineret med anti-hsp90-antistoffer DK1267925T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008305.5A GB0008305D0 (en) 2000-04-06 2000-04-06 Treatment of fungal infections
PCT/GB2001/001195 WO2001076627A1 (fr) 2000-04-06 2001-03-20 Traitement des infections fongiques avec des antifongiques a base d'inhibiteur de synthase polyene ou beta glucane combines a des anticorps anti-hsp90

Publications (1)

Publication Number Publication Date
DK1267925T3 true DK1267925T3 (da) 2007-10-15

Family

ID=9889204

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01911971T DK1267925T3 (da) 2000-04-06 2001-03-20 Behandling af svampeinfektion mod antifungale polyener eller beta-glucansyntesehæmmere kombineret med anti-hsp90-antistoffer

Country Status (19)

Country Link
US (4) US20030180285A1 (fr)
EP (4) EP1267925B8 (fr)
JP (1) JP2003530357A (fr)
CN (3) CN1420786A (fr)
AT (1) ATE364396T1 (fr)
AU (2) AU2001240890B2 (fr)
BR (1) BR0109846A (fr)
CA (1) CA2401836A1 (fr)
CY (1) CY1106794T1 (fr)
DE (1) DE60128893T2 (fr)
DK (1) DK1267925T3 (fr)
ES (1) ES2287105T3 (fr)
GB (1) GB0008305D0 (fr)
NO (1) NO20024815L (fr)
NZ (1) NZ520899A (fr)
PL (1) PL358394A1 (fr)
PT (1) PT1267925E (fr)
RU (1) RU2262952C2 (fr)
WO (1) WO2001076627A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050129665A1 (en) * 2002-07-25 2005-06-16 Martin Friedlander Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
US7651689B2 (en) * 2002-11-15 2010-01-26 Albert Einstein College Of Medicine Of Yeshiva University Methods of applying ionization radiation for therapy of infections
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
EP1457499A1 (fr) * 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibiteurs de protéine de choc thermique (HSP90) extracellulaire
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
GB0409077D0 (en) * 2004-04-23 2004-05-26 Neutec Pharma Plc Treatment of fungal infections
US20080038267A1 (en) * 2004-07-02 2008-02-14 Neutec Pharma Limited Treatment Of Cancer
JP2008504355A (ja) * 2004-07-02 2008-02-14 ニュウテック ファーマ リミテッド 癌の処置
WO2006091459A2 (fr) * 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions et methodes permettant de traiter la permeabilite vasculaire
CA2604042C (fr) * 2005-04-13 2016-06-21 Astex Therapeutics Limited Compositions pharmaceutiques
GB0600168D0 (en) * 2006-01-05 2006-02-15 Neutec Pharma Plc A therapeutic composition
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
WO2008091692A2 (fr) * 2007-01-25 2008-07-31 Joslin Diabetes Center, Inc. Procédés de diagnostic, de traitement et de prévention de la perméabilité vasculaire accrue
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
WO2008132174A1 (fr) * 2007-04-27 2008-11-06 Novartis Ag Composition d'immunoglobulines
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
CN113845591B (zh) * 2018-10-30 2023-10-31 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用
CN111679069A (zh) * 2019-12-31 2020-09-18 安徽中医药大学 一种通过耳道念珠菌细胞壁重构来评价中药单体抗真菌作用的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8915019D0 (en) 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
GB2270076A (en) * 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
US6375955B1 (en) * 1995-09-22 2002-04-23 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6365165B1 (en) * 1995-09-22 2002-04-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US5834592A (en) * 1995-09-22 1998-11-10 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides

Also Published As

Publication number Publication date
CN101095952A (zh) 2008-01-02
GB0008305D0 (en) 2000-05-24
RU2002129510A (ru) 2004-03-27
JP2003530357A (ja) 2003-10-14
US20100285029A1 (en) 2010-11-11
ES2287105T3 (es) 2007-12-16
AU2001240890B2 (en) 2005-06-16
US20080193459A1 (en) 2008-08-14
BR0109846A (pt) 2003-06-03
PL358394A1 (en) 2004-08-09
US20030180285A1 (en) 2003-09-25
PT1267925E (pt) 2007-09-04
ATE364396T1 (de) 2007-07-15
EP2011512A1 (fr) 2009-01-07
CY1106794T1 (el) 2012-05-23
CA2401836A1 (fr) 2001-10-18
EP1818062A3 (fr) 2007-10-24
NZ520899A (en) 2005-03-24
WO2001076627A8 (fr) 2001-11-15
EP1267925B1 (fr) 2007-06-13
WO2001076627A1 (fr) 2001-10-18
CN1420786A (zh) 2003-05-28
DE60128893T2 (de) 2007-12-06
RU2262952C2 (ru) 2005-10-27
NO20024815D0 (no) 2002-10-04
US20080181884A1 (en) 2008-07-31
EP1267925A1 (fr) 2003-01-02
CN101683525A (zh) 2010-03-31
EP1818062A1 (fr) 2007-08-15
DE60128893D1 (de) 2007-07-26
AU4089001A (en) 2001-10-23
EP1267925B8 (fr) 2007-08-29
EP1852128A1 (fr) 2007-11-07
NO20024815L (no) 2002-12-02

Similar Documents

Publication Publication Date Title
DK1267925T3 (da) Behandling af svampeinfektion mod antifungale polyener eller beta-glucansyntesehæmmere kombineret med anti-hsp90-antistoffer
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1116632T1 (el) Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
CY2012019I1 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
DK2316852T3 (da) Stabiliserede enkeltdomæne-antistoffer
BRPI0406574A (pt) Conjugados de anticorpo - antraciclina
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
DK1578397T3 (da) Humane monoklonale antistoffer mod CD25
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
NZ602256A (en) Monoclonal antibodies against the rgm a protein and uses thereof
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
NO20071436L (no) Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater
CL2008001258A1 (es) Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria.
CY1112288T1 (el) Θεραπεια του καρκινου με αντισωματα κατα της il-1a
DK2330132T3 (da) Antistoffer mod MMP2 eller MMP9 og farmaceutiske sammensætninger deraf til hæmning af deres metalloproteinaktivitet
EP1789027A4 (fr) Utilisation therapeutique d'anticorps d'antigene anti-tf
DK1534750T3 (da) Terapeutisk brug af monoklonale antistoffer mod angiotensin-II type-1 receptoren
CY1109121T1 (el) Θεραπεια μυκητιασικων μολυνσεων
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
FI20011055L (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
DK1398325T3 (da) Monoklonalt antistof, specifikt for en epitop af inaktiveret felint immundeficiens-kodet glykoprotein
DK1503799T3 (da) Immunogent, monoklonalt antistof
WO2022212654A3 (fr) Anticorps monoclonaux à réaction croisée contre les coronavirus
BR0315018A (pt) Uso de anticorpos dos receptores de il-2 para prevenir toxicidade associada à terapia antimicótica com anfotericina b
CY1116949T1 (el) M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου